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TRENDS IN PHARMACEUTICAL SPENDING GROWTH IN THE
UNITED STATES, 1998–2002
Roberts WM, Rindress D
BioMedCom Consultants, inc, Montréal, QC, Canada
OBJECTIVES: Increasing drug utilization, increasing average
drug cost, or both may be responsible for pharmaceutical spend-
ing growth in the US. Recent trends in outpatient drug utiliza-
tion were examined to assess the relative contribution of both
factors. METHODS: Five-year trends in expenditures and pre-
scribing rates for outpatient drugs were estimated by analyzing
the most recently available nationally representative data from
the Medical Expenditure Panel Survey (MEPS), National Ambu-
latory Medical Care Survey (NAMCS) and National Hospital
Ambulatory Medical Care Survey (NHAMCS). RESULTS:
MEPS data indicate that from 1998 to 2002 outpatient pre-
scription drug expenditures (excluding inpatient prescriptions,
over-the-counter medicines and samples) nearly doubled from
$78 billion to $151 billion. Total number of prescription drug
purchases increased by 37%, while average cost per prescription
increased by 41%. Over the same period, NAMCS and
NHAMCS data reveal that physician ofﬁce, hospital outpatient
department and emergency department visits accounted for
81%, 8%, and 11%, respectively, of medications given at out-
patient visits (prescribed or provided). For visits at which med-
ications were given, number of visits increased by 6.9%, 12.6%
and 16.6%, and number of medications per visit increased by
6.6%, 8.5%, and 13.5% for physician ofﬁce, outpatient depart-
ment, and emergency department visits, respectively. However,
the proportion of physician ofﬁce and outpatient department
visits at which drugs were given remained relatively constant at
approximately 65%. The proportion of emergency department
visits at which drugs were given increased from 71.3% to 75.8%.
CONCLUSION: Total drug utilization and average drug cost
both increased to a comparable degree between 1998 and 2002.
Although the total number of visits and the average number of
drugs given per visit increased, the proportion of health care
visits at which outpatients received drugs or prescriptions was
relatively stable. Increased utilization was greater for emergency
department visits than for physician ofﬁce or hospital outpatient
department visits.
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IMPACT OF HEALTH INSURANCE ON HEALTH-RELATED
QUALITY OF LIFE
Bharmal M,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Relationships between health insurance status
and health-related quality of life (HRQOL) were investigated.
METHODS: The 2000 Medical Expenditure Panel Survey data
were analyzed to examine relationships between health insurance
status and health-related quality of life. HRQOL was measured
using the SF-12 Physical Component Summary (PCS) and SF-12
Mental Component Summary (MCS). The sample included
adults aged 25 to 64 years who did not have Medicaid or
Medicare coverage. Respondents who were insured for only part
of the year were excluded from the analysis. Survey weighted
multiple regression models using SAS version 8.2 were used for
the analysis. The analysis controlled for sociodemographic vari-
ables, attitudinal variables and medical conditions. The analysis
also investigated and controlled for the possible endogeneity of
the health insurance status variable in the models. RESULTS: Of
the 8141 adults in the sample that met inclusion criteria, 1449
(17.79%) were without health insurance for the entire year. Tests
were positive for endogeneity of the health insurance status in
PCS model but not in the MCS model. After adjusting for covari-
ates that included age, gender, race, education, income, attitude
towards the value of health insurance and health care, and pres-
ence or absence of each of nine reported medical conditions, indi-
viduals without health insurance had signiﬁcantly lower PCS
scores than those with health insurance. Individuals with family
income above 200% of federal poverty level had a higher detri-
mental effect of absence of health insurance on PCS compared
to individuals with family income below 200% of federal
poverty level (Beta = -10.85 versus Beta = -8.21). The adjusted
adverse effect of no health insurance also was signiﬁcant in the
MCS model (Beta = -1.43; SE = 0.49). CONCLUSIONS: The
detrimental effect of lack of health insurance on HRQOL equals
or exceeds the detrimental effect of many serious medical con-
ditions on HRQOL.
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FINANCING TO MEDICINES IN MEXICO
Molina R
Universidad Autonoma Metropolitana Campus Iztapalapa, Mexico,
City, Mexico
OBJECTIVES: The objectives of this work are oriented in the
ﬁrst place to discuss the modalities of the ﬁnancing of medicines,
in special to study the characteristics of the access forms and
ﬁnancing to medicines according to the level of the income of
the household in Mexico. In the industrialized countries the
forms of ﬁnancing of medicines, like the ﬁnancing to the services
of health is made by means of some scheme of copayment or
subsidy the vulnerable groups. But in the non industrialized
countries the main form of ﬁnancing of medicines comes 
from the out-of-pocket household which is very inequitative.
METHODS: For this study the registries of the surveys of house-
holds income by 2002 of Mexico to study the medicine expen-
diture by deciles of income. With this information the coefﬁcients
of Gini and the curve of Lorenz are considered. Additionally it
is used the public and private information on the price and the
cost in medicines. RESULTS: The access to medicines in Mexico
is not related to the necessities of health but to the availability
of income of the households, because 85 % of the medicines are
acquired by means of the out-of-pocket money of households,
because the social security provides free of charge medicines only
15 % of them. The income survey cost of the homes sample that
39 % of the medicine consumption in the private market both
make last deciles of greater income; also one is that the con-
sumption of the decil of greater income is four times superior to
the one of the population with smaller income. CONCLU-
SIONS: The access to medicines in Mexico are not related to
health needs but to household income. Also medicine prices 
constitutes an effective barrier to medicine acces to a suitable
therapy.
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OBJECTIVES: To investigate the determinants of expenditures
on pharmaceuticals and other medical non-durables in OECD
(Organization for Economic Cooperation and Development)
countries. METHODS: This is a cross-sectional study using year
2000 data for twenty-seven OECD countries. The dependent
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variable is per capita pharmaceutical and other medical non-
durable expenditures. Explanatory variables investigated include
per capita GDP (Gross Domestic Product), % of elderly popu-
lation (65+ years), % of population with higher education
(college+), school expectancy, calorie intake per capita per day,
alcohol consumption in liters per capita (age 15+), % of expen-
ditures on pharmaceuticals and other medical non-durables
ﬁnanced by the public sector, number of practicing physicians,
% of population with public health care coverage, number of
doctor consultations per capita and % urbanized. All monetary
values were converted into US dollars based on GDP purchasing
power parity. A log-linear (constant elasticity) regression model
was used. RESULTS: The ﬁnal model included 6 explanatory
variables with an adjusted R2 = 0.744. The White test was used
to correct heteroskedasticity. The natural log of GDP per capita
(b = 0.455, p = 0.003), percent of elderly population (b = 0.039,
p = 0.01), number of doctor consultations (b = 0.028, p = 0.008),
and calories intake (b = 0.0003, p = 0.002) had positive, statis-
tically signiﬁcant effects on pharmaceutical expenditures at á 
< 0.01. Percent of population with higher education (b = 0.012,
p = 0.22) and public ﬁnancing (b = -0.001, p = 0.43) were not
signiﬁcant. Alcohol consumption (another indicator of lifestyle
behaviors); number of physicians and public health care cover-
age (indicators of relative size of the health care system); urban-
ization (indicator of development); and school expectancy
(another indicator of educational development) did not con-
tribute to the model. CONCLUSIONS: OECD countries with
more wealth, more elderly people, more doctor consultations,
and more calorie intake tend to spend more on pharmaceuticals
and other medical non-durables. Size of the health care system
and ﬁnancing methods do not explain differences in pharma-
ceutical expenditures.
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ANALYSIS OF PRESCRIBING PATTERN WITH THE NEGATIVE
LIST FORMULARY SYSTEM IN KOREA
Lee EK, Park EJ
Korea Institute for Health and Social Affairs, Seoul, South Korea
OBJECTIVES: All approved pharmaceutical products in Korea
are available for reimbursement except some products on the
negative list. The aim of this study is to examine how many prod-
ucts are actually prescribed by doctors and to compare the 
prescribing patterns in inpatient and outpatient settings.
METHODS: Prescription data were obtained from the Korean
National Health Insurance claims database of April 2004 for all
the hospitals and clinics in Korea. The numbers of prescribed
products and ingredients were calculated along with the drug
expenditure incurred. RESULTS: In April 2004, 19,452 phar-
maceutical products (5120 ingredients) were on the list of reim-
bursable drug formulary. Among them 9423 products (3208
ingredients), 48.2% of the reimbursable products, were actually
prescribed for inpatients. For outpatients, 11,823 products
(3731 ingredients), 60.8% of reimbursable products, were pre-
scribed. Although more than 9000 pharmaceutical products
were prescribed by doctors, top quintile high-expenditure drugs
of 1885 took up 94% of total drug expenditure for inpatients,
whereas top quintile 2365 products did 91.5% for outpatients.
Also, top quintile high-expenditure ingredients of 632 accounted
for 93% of total drug expenditure for inpatients, whereas those
of 746 ingredients did 92% for outpatients. CONCLUSIONS:
Unlike in western societies, more products and ingredients were
prescribed for outpatients than for inpatients in Korea. This
study also showed that although various pharmaceutical prod-
ucts were prescribed, the top 20% (high-expenditure drugs) of
all products and ingredients took up the lion’s share of total drug
expenditure. It suggests that there is a need of introduction 
of positive list formulary system for the efﬁcient drug beneﬁt
management.
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THE CURRENT AND FUTURE OF PHARMACOECONOMICS IN
UKRAINE
Zaliska OM, Parnovsky B
Lviv National Medical University named Danylo Galitsky, Lviv, Ukraine
OBJECTIVES: In Ukraine the government authorizes the State
program of maintenance of the population by medical products
for 2004–2010, which provides use of pharmacoeconomic analy-
sis methods. The State Formulary for pharmaceutical provision
are formed. METHODS: We have analyzed all available phar-
macoeconomic studies published in Ukraine for 1998–2004 to
assess methodological problems and potential for future use of
pharmacoeconomics in drug policy. RESULTS: We have estab-
lished, that the quantity of published pharmacoeconomic
researches has increased in 7.3 times. Methodological quality is
generally insufﬁcient. Cost-minimization is the preferred tech-
nique although differences in effectiveness are not properly
assessed. Few studies desribe costing and cost-effectiveness
methodologies. Modeling studies are weak due absence of epi-
demiological and economical database. Societal perspective is
rarely used—the health care perspective prevails. Little study
exist in Qol measurement and cost-utility techniques. Industry
use of pharmacoeconomics is mainly for supporting marketing
and sales. Physicians are increasingly receptive of pharmaco-
economic analysis, but little value on modeling approaches. We
develop methodical recommendations on use of pharmaco-
economic analysis methods in Ukraine, authorized by Ministry
of Health. We have conducted the analysis of consumption of
antidiabetic agents in the deﬁned daily doses. We published 
the circular “A Technique of pharmacoeconomical analysis 
‘cost-effectiveness’ for deﬁnition of need in medicinal tools in
Ukraine”. CONCLUSION: Pharmacoeconomics must improve
methodological standarts in Ukraine. This is a task for both 
government and industry with the purpose of creation of State
Formulary.
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OBJECTIVES: To investigate the quality and completeness of
economic models submitted by pharmaceutical manufacturers to
health plans under the Academy of Managed Care Pharmacy
(AMCP) Format for formulary submissions, and to compare eco-
nomic models of “me-too” versus drugs judged to have signiﬁ-
cant competitive edge. METHODS: We analyzed economic
models included in AMCP-Format dossiers submitted by phar-
maceutical companies to the pharmacy services staff of Premera
Blue Cross (Mountlake Terrace, WA, enrollment 1.5 million) in
2003. “Economic models” were deﬁned as mathematical simu-
lations that combined clinical and cost data to estimate the eco-
nomic value of a drug. We assessed models’ compliance with
criteria recommended by the Panel on Cost-Effectiveness in
Health and Medicine, including: justiﬁcation of model type;
statement of time horizon and discount rate; discussion and
reporting of productivity changes; separate reporting of resource
quantities from prices; comparison against relevant alternatives;
